Growth Metrics

Harte Hanks (HHS) Current Deferred Revenue (2016 - 2025)

Harte Hanks (HHS) has disclosed Current Deferred Revenue for 16 consecutive years, with $2.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue fell 27.71% to $2.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.5 million, a 27.71% decrease, with the full-year FY2024 number at $1.6 million, down 50.27% from a year prior.
  • Current Deferred Revenue was $2.5 million for Q3 2025 at Harte Hanks, up from $1.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $7.0 million in Q3 2022 to a low of $1.6 million in Q4 2024.
  • A 5-year average of $4.4 million and a median of $4.6 million in 2022 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 41.51% in 2022, then crashed 50.27% in 2024.
  • Harte Hanks' Current Deferred Revenue stood at $3.9 million in 2021, then rose by 16.44% to $4.6 million in 2022, then crashed by 30.39% to $3.2 million in 2023, then plummeted by 50.27% to $1.6 million in 2024, then skyrocketed by 54.69% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for HHS's Current Deferred Revenue are $2.5 million (Q3 2025), $1.8 million (Q2 2025), and $2.5 million (Q1 2025).